# Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer

> **NCT00065429** · PHASE1,PHASE2 · COMPLETED · sponsor: **ImmunoGen, Inc.** · enrollment: 64 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** BB-10901

## Key facts

- **NCT ID:** NCT00065429
- **Lead sponsor:** ImmunoGen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-04
- **Primary completion:** 2008-11
- **Final completion:** 2008-12
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2012-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00065429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00065429, "Safety Study Using Weekly Infusions of BB-10901 in Patients With Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00065429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*